Revisiting the vicious circle of dry eye disease: A focus on the pathophysiology of meibomian gland dysfunction

British Journal of Ophthalmology

Volumn 100, Issue 3, 2016, Pages 300-306

  Baudouin, Christophe ^a,b   Messmer, Elisabeth M ^c   Aragona, Pasquale ^d   Geerling, Gerd ^e   Akova, Yonca A ^f   Benítez Del Castillo, José ^g   Boboridis, Kostas G ^h   Merayo Lloves, Jesús ⁱ   Rolando, Maurizio ^j   Labetoulle, Marc ^k  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f BAYINDIR HOSPITAL   (Turkey)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ UNIVERSITY OF OVIEDO   (Spain)

^j UNIVERSITY OF GENOA   (Italy)

^k BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUNCTIVITIS; CORNEA DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRY EYE; EYELID DISEASE; HUMAN; HYPEROSMOLARITY; INFLAMMATION; MEIBOMIAN GLAND DYSFUNCTION; MICROBIAL GROWTH; MICROFLORA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; TEAR FILM; CLASSIFICATION; DRY EYE SYNDROMES; EYELID DISEASES; MEIBOMIAN GLAND;

DRY EYE SYNDROMES; EYELID DISEASES; HUMANS; MEIBOMIAN GLANDS;

EID: 84959530843     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-307415     Document Type: Review

References (61)

1. Knop E, Knop N, Millar T, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian Gland. Invest Ophthalmol Vis Sci 2011;52:1938-78.
2. McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer. Ocul Surf 2003;1:97-106.
3. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2013;11:246-58.
4. Rolando M, Papadia M. Diagnosis and management of the lid and ocular surface disorders. In: Asbell PA, Lemp MA, eds. Dry eye disease: the clinician's guide to diagnosis and treatment. New York: Thieme Medical Publishers, 2006:63-83.
5. International Dry Eye Workshop. Report of the International Dry Eye Workshop (DEWS). Ocul Surf 2007;5:61-204.
6. Baudouin C. [A new approach for better comprehension of diseases of the ocular surface]. J Fr Ophtalmol 2007;30:239-46.
7. Schaumberg DA, Nichols JJ, Papas EB, et al. The International Workshop on Meibomian Gland Dysfunction: report of the subcommitee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011;52:1994-2005.
8. Foulks GN, Nichols KK, Bron AJ, et al. Improving awareness, identification, and management of meibomian gland dysfunction. Ophthalmology 2012;119:S1-12.
9. Lemp MA, Foulks GN, Pepose JS. Evaluation of tear osmolarity in non-Sjogren and Sjogren syndrome dry eye patients with the TearLab system. Cornea 2013;32:379-81.
10. Fenga C, Aragona P, Cacciola A, et al. Meibomian gland dysfunction and ocular discomfort in video display terminal workers. Eye 2008;22:91-5.
11. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci 2011;52:1922-9.
12. Uchino M, Dogru M, Yagi Y, et al. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci 2006;83:797-802.
13. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-8.
14. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114-19.
15. Lekhanont K, Rojanaporn D, Chuck RS, et al. Prevalence of dry eye in Bangkok, Thailand. Cornea 2006;25:1162-7.
16. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 2003;110:1096-101.
17. Viso E, Rodriguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012;53:2601-6.
18. Arita R, Itoh K, Maeda S, et al. Efficacy of diagnostic criteria for the differential diagnosis between obstructive meibomian gland dysfunction and aqueous deficiency dry eye. Jpn J Ophthalmol 2010;54:387-91.
19. Stanek S. Meibomian gland status comparison between active duty personnel and U.S. veterans. Mil Med 2000;165:591-3.
20. Tong L, Chaurasia SS, Mehta JS, et al. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci 2010;51:3449-54.
21. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Definition and Classification Subcommittee. Invest Ophthalmol Vis Sci 2011;52:1930-7.
22. Parfitt GJ, Xie Y, Geyfman M, et al. Absence of ductal hyper-keratinization in mouse age-related meibomian gland dysfunction (ARMGD). Aging (Albany NY) 2013;5:825.
23. Nien CJ, Massei S, Lin G, et al. Effects of age and dysfunction on human meibomian glands. Arch Ophthalmol 2011;129:462-9.
24. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf 2003;1:107-26.
25. Lozato PA, Pisella PJ, Baudouin C. [The lipid layer of the lacrimal tear film: physiology and pathology]. J Fr Ophtalmol 2001;24:643-58.
26. Borchman D, Foulks GN, Yappert MC, et al. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. Invest Ophthalmol Vis Sci 2011;52:3805.
27. Nien CJ, Paugh JR, Massei S, et al. Age-related changes in the meibomian gland. Exp Eye Res 2009;89:1021-7.
28. Ibrahim OM, Dogru M, Matsumoto Y, et al. Oxidative stress induced age dependent meibomian gland dysfunction in Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice. PLoS ONE 2014;9:e99328.
29. Villani E, Canton V, Magnani F, et al. The aging meibomian gland: an in vivo confocal study. Invest Ophthalmol Vis Sci 2013;54:4735-40.
30. Labetoulle M, Baudouin C. From pathogenic considerations to a simplified decision-making schema in dry eye disease. J Fr Ophtalmol 2013;36:543-7.
31. Hamano T, Horimoto K, Lee M, et al. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol 1996;40:62-5.
32. Nakamura M, Hikida M, Nakano T, et al. Characterization of water retentive properties of hyaluronan. Cornea 1993;12:433-6.
33. Simmons PA, Chang-Lin J-E, Chung Q, et al. Effect of compatible solutes on transepithelial electrical resistance and uptake in primary rabbit corneal epithelial cell layers model. Presented at the Association for Research in Vision and Ophthalmology (ARVO), 2007.
34. Bayhan SA, Bayhan HA, Muhafiz E, et al. Effects of osmoprotective eye drops on tear osmolarity in contact lens wearers. Can J Ophthalmol 2015;50:283-9.
35. Geerling G, Tauber J, Baudouin C, et al. The International Workshop on Meibomian Gland Dysfunction: report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction. Invest Ophthalmol Vis Sci 2011;52:2050-64.
36. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013;7:1797-803.
37. Kosik-Bogacka DI, Lanocha N, Lanocha A, et al. Role of Demodex folliculorum in the pathogenesis of blepharitis. Acta Ophthalmol 2012;90:e579.
38. Murillo N, Aubert J, Raoult D. Microbiota of Demodex mites from rosacea patients and controls. Microb Pathog 2014;71-72:37-40.
39. Chang M, Lee H, Park MS, et al. The clinical characteristics and new classification of sticky eyelid syndrome in East Asian patients. Acta Ophthalmol 2014;92: e667-70.
40. Alvarenga LS, Mannis MJ. Ocular rosacea. Ocul Surf 2005;3:41-58.
41. Bron AJ, Yokoi N, Gafney E, et al. Predicted phenotypes of dry eye: proposed consequences of its natural history. Ocul Surf 2009;7:78-92.
42. Corrales RM, de Paiva CS, Li DQ, et al. Entrapment of conjunctival goblet cells by desiccation-induced cornification. Invest Ophthalmol Vis Sci 2011;52:3492-9.
43. Takahashi H, Asano-Kato N, Nakamura S, et al. Interferon-gamma-dependent stimulation of human involucrin gene expression: STAT1 (signal transduction and activators of transcription 1) protein activates involucrin promoter activity. Biochem J 1999;334:797-802.
44. Chen Z, Tong L, Li Z, et al. Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK. Invest Ophthalmol Vis Sci 2008;49:539-49.
45. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999;159:1359-63.
46. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23.
47. Arita R, Morishige N, Koh S, et al. Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study. Ophthalmology 2015;122:925-33.
48. Qazi Y, Aggarwal S, Hamrah P. Image-guided evaluation and monitoring of treatment response in patients with dry eye disease. Graefes Arch Clin Exp Ophthalmol 2014;252:857-72.
49. Menzies KL, Srinivasan S, Prokopich CL, et al. Infrared imaging of meibomian glands and evaluation of the lipid layer in Sjögren's syndrome patients and nondry eye controls. Invest Ophthalmol Vis Sci 2015;56:836-41.
50. Ban Y, Ogawa Y, Ibrahim OM, et al. Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Mol Vis 2011;17:2533.
51. Villani E, Beretta S, De CM, et al. In vivo confocal microscopy of meibomian glands in Sjogren's syndrome. Invest Ophthalmol Vis Sci 2011;52:933-9.
52. Qazi Y, Kheirkhah A, Blackie C, et al. In vivo detection of clinically non-apparent ocular surface inflammation in patients with meibomian gland dysfunction-associated refractory dry eye symptoms: a pilot study. Eye 2015;29:1099-110.
53. Gao YY, Di Pascuale MA, Li W, et al. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol 2005;89:1468-73.
54. Bilkhu PS, Naroo SA, Wolffsohn JS. Randomised masked clinical trial of the MGDRx eyebag for the treatment of meibomian gland dysfunction-related evaporative dry eye. Br J Ophthalmol 2014;98:1707-11.
55. Benitez Del Castillo JM, Kaercher T, Mansour K, et al. Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction. Clin Ophthalmol 2014;8:2019-27.
56. Finis D, Hayajneh J, Konig C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow): system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf 2014;12:146-54.
57. Doan S, Chiambaretta F, Baudouin C. Evaluation of an eyelid warming device (Blephasteam) for the management of ocular surface diseases in France: the ESPOIR study. J Fr Ophtalmol 2014;37:763-72.
58. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 2007;62:483-8.
59. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004;45:4302-11.
60. Knop E, Knop N. [Meibomian glands: part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD)]. Ophthalmologe 2009;106:980-7.
61. Baudouin C. [Revisiting meibomian gland dysfunction]. J Fr Ophtalmol 2014;37:757-62.